ALKBH5 facilitates tumor progression via an m6A-YTHDC1-dependent mechanism in glioma
Cancer Letters · 2025
DOI: 10.1016/j.canlet.2025.217439 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Letters, 2025. Verfasst von Chenyang Wang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosurgery Center, The National Key Clinical Specialty, The Engineering Technology Research Center of Education Ministry of China on …. Hauptthemen laut MEDLINE: AlkB Homolog 5, RNA Demethylase, Glioma, Adenosine, Brain Neoplasms. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
-methyladenosine (m6A) methylation, is a well-known epigenetic modification involved in various biological processes, including tumorigenesis. However, the role of AlkB homolog 5 (ALKBH5), a critical component of m6A modification, remains unclear in glioma. This study investigates the function of ALKBH5 in glioma progression and its potential as a therapeutic target. We found that ALKBH5 expression was dramatically increased in glioma, and high expression of ALKBH5 predicted poor prognosis. Overexpression of ALKBH5 promotes cell proliferation, migration, and invasion in vitro and accelerates tumor growth in vivo. Furthermore, m6A-MeRIP-seq, MeRIP-qPCR, RNA pulldown, and immunoprecipitation assays revealed that the transcription factor, forkhead box protein O1 (FOXO1), was the potential target of ALKBH5. Mechanistically, ALKBH5 facilitates glioma progression by demethylating m6A-modified FOXO1 mRNA, thereby destroying FOXO1 stability and expression through a YTHDC1-dependent pathway. The downregulated FOXO1 interacts with β-catenin, increasing its nuclear accumulation and thus promoting oncogenic Wnt/β-catenin signaling. Our findings suggest that targeting the ALKBH5/FOXO1 axis may provide a novel therapeutic strategy for glioma treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurosurgery Center, The National Key Clinical Specialty, The Engineering Technology Research Center of Education Ministry of China on Diagnosis and Treatment of Cerebrovascular Disease, Guangdong Provinci…
- Department of Neurosurgery, The Affiliated Tumor Hospital of Zhengzhou University, Zhengzhou, 450008, China.
- Department of Geriatrics, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong, 510282, China.
Zitieren
APA
Wang, C., Xu, N., Zhong, X., Liu, B., Tang, W., He, Z., Bu, X., Cao, M., Zeng, H., & Guo, H. (2025). ALKBH5 facilitates tumor progression via an m6A-YTHDC1-dependent mechanism in glioma. Cancer Letters. https://doi.org/10.1016/j.canlet.2025.217439
Vancouver
Wang C, Xu N, Zhong X, Liu B, Tang W, He Z, et al. ALKBH5 facilitates tumor progression via an m6A-YTHDC1-dependent mechanism in glioma. Cancer Letters. 2025. doi:10.1016/j.canlet.2025.217439
BibTeX
@article{Wang2025,
author = {Wang, Chenyang and Xu, Ningbo and Zhong, Xiangyang and Liu, Boyang and Tang, Wenhui and He, Zhenyan and Bu, Xiaolu and Cao, Mengyao and Zeng, Huijun and Guo, Hongbo},
title = {ALKBH5 facilitates tumor progression via an m6A-YTHDC1-dependent mechanism in glioma},
journal = {Cancer Letters},
year = {2025},
doi = {10.1016/j.canlet.2025.217439}
}
EUVIMED